Toby Maher discusses the results of the SENSCIS trial, looking at the safety and efficacy of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD) treated with mycophenolate. Read the full article: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30458-6/fulltext

Toby Maher discusses the results of the SENSCIS trial, looking at the safety and efficacy of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD) treated with mycophenolate. Read the full article: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30458-6/fulltext

Toby Maher discusses the results of the SENSCIS trial, looking at the safety and efficacy of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD) treated with mycophenolate. Read the full article: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30458-6/fulltext

Treatment options in patients with systemic sclerosis-associated interstitial lung disease

Editors speak to the journal’s authors to explore their research and its impact on people’s health, health care, and health policy in this regular podcast.

Share Treatment options in patients with systemic sclerosis-associated interstitial lung disease

Sign up to save your podcasts

Treatment options in patients with systemic sclerosis-associated interstitial lung disease

Treatment options in patients with systemic sclerosis-associated interstitial lung disease